Clinical Trials
60 trialsNCT07079475 2026-05-26
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT07375316 2026-05-26
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT07005102 2026-05-22
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT03191149 2026-05-18
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04181060 2026-05-18
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06417814 2026-05-14
TROPION-Lung15
AstraZeneca
Phase 3 Recruiting
NCT06486142 2026-05-14
ERIS
Region Skane
Phase 3 Recruiting
NCT05647122 2026-05-11
EGRET
AstraZeneca
Phase 1 Recruiting
NCT07329322 2026-05-11
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06670196 2026-05-08
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05401110 2026-05-07
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Cedars-Sinai Medical Center
Phase 1 Recruiting
NCT06014827 2026-05-07
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06618287 2026-05-07
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05642572 2026-05-06
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Recruiting
NCT06350097 2026-05-06
TROPION-Lung14
AstraZeneca
Phase 3 Recruiting
NCT05624996 2026-05-04
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT04591002 2026-04-30
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Samsung Medical Center
Phase 2 Recruiting
NCT05528458 2026-04-28
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Samsung Medical Center
Phase 2 Recruiting
NCT07535437 2026-04-21
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06838273 2026-04-20
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07323641 2026-04-20
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05142189 2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
NCT06741085 2026-04-13
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07295821 2026-04-08
NSCLC
AstraZeneca
Phase 2 Recruiting
NCT05785741 2026-04-06
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT04665206 2026-04-02
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
Phase 1/2 Recruiting
NCT07505173 2026-04-01
HOPE-WBRT
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04762199 2026-03-31
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Emory University
Phase 1 Recruiting
NCT06538038 2026-03-27
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
NCT06970639 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07379476 2026-02-12
Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
Chinese University of Hong Kong
Phase 2 Recruiting
NCT06507306 2026-02-06
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
Phase 1 Recruiting
NCT04486833 2026-01-21
Acclaim-1
Genprex, Inc.
Phase 1/2 Recruiting
NCT07315113 2026-01-02
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Nuvectis Pharma, Inc.
Phase 1 Recruiting
NCT04780568 2025-12-09
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT07229729 2025-12-01
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07206498 2025-11-28
WAYWIN103
Wayshine Biopharm, Inc.
Phase 1/2 Recruiting
NCT07058519 2025-11-26
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Shanghai Chest Hospital
Phase 2 Recruiting
NCT04410796 2025-11-06
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06304441 2025-09-29
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
Guangzhou Medical University
Phase NA Recruiting
NCT06574347 2025-05-21
KYLIN-2
Avistone Biotechnology Co., Ltd.
Phase 2 Recruiting
NCT06498986 2025-05-07
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06895928 2025-04-22
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06829459 2025-04-08
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Shanghai JMT-Bio Inc.
Phase 3 Recruiting
NCT05281406 2025-02-21
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
Goethe University
Phase 2 Recruiting
NCT06071013 2025-01-23
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
Phase 1/2 Recruiting
NCT06735391 2024-12-16
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Shanghai JMT-Bio Inc.
Phase 3 Recruiting
NCT05948813 2024-11-21
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
TYK Medicines, Inc
Phase 2 Recruiting
NCT04322890 2024-10-22
PIKACHU
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT06532149 2024-08-09
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting